Welcome to our dedicated page for Adial Pharmaceuticals SEC filings (Ticker: ADIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Adial Pharmaceuticals’ dense biotech disclosures can feel like navigating a clinical protocol—hundreds of pages on trial endpoints, FDA feedback, and financing terms. Yet missing a single footnote on AD04’s pivotal study or an executive’s stock sale could change your thesis overnight.
Stock Titan solves this problem. Our AI-powered engine delivers Adial Pharmaceuticals SEC filings explained simply, pulling key data from every submission the moment it hits EDGAR. Whether you need the latest Adial Pharmaceuticals quarterly earnings report 10-Q filing, an Adial Pharmaceuticals 8-K material events explained, or a full Adial Pharmaceuticals annual report 10-K simplified, you’ll get concise summaries, red-flag highlights, and side-by-side comparisons—no scientific dictionary required.
Have specific questions? Ask them naturally: “How is the cash runway after Phase III?” or “Show me Adial Pharmaceuticals insider trading Form 4 transactions.” Our platform surfaces Adial Pharmaceuticals Form 4 insider transactions real-time, tracks Adial Pharmaceuticals executive stock transactions Form 4, and links them to catalyst dates. Dive deeper with AI-driven Adial Pharmaceuticals earnings report filing analysis, parse the Adial Pharmaceuticals proxy statement executive compensation, or benchmark risk factors across quarters—all in one place.
- Monitor trial milestones inside 10-K, 10-Q and 8-K forms
- Spot insider sentiment before material announcements
- Compare R&D spend and dilution scenarios instantly
- Export data to your models for evidence-based decisions
Stop wading through PDFs. Start understanding Adial Pharmaceuticals SEC documents with AI—complete coverage, real-time alerts, and insights that let you focus on investment strategy, not document hunting.
Adial Pharmaceuticals (ADIL) is a clinical-stage biopharmaceutical company developing AD04 for alcohol use disorder with a precision‑medicine genetic focus. At June 30, 2025 the company held $5.9 million in cash and cash equivalents and reported a $4.19 million net loss for the six months ended June 30, 2025, leaving an accumulated deficit of $86.2 million.
Management received approximately $5.3 million of net proceeds from warrant exercises and equity issuances in May–June 2025 and completed a June 2025 best efforts offering that generated about $3.0 million net. The company states these funds are sufficient to meet current commitments into the second quarter of 2026 but explicitly notes substantial doubt about its ability to continue as a going concern and that additional capital will be required for planned Phase 3 trials.
Key operational positives disclosed include a favorable FDA response on an in‑vitro bridging strategy and an issued U.S. patent (April 15, 2025) covering AD04 administration for patients with specified genetic markers. The filing also discloses material weaknesses in internal controls and multiple warrant programs and shareholder approvals that create meaningful potential dilution.
FAQ
What is the current stock price of Adial Pharmaceuticals (ADIL)?
What is the market cap of Adial Pharmaceuticals (ADIL)?
